Role of Intravenous Dexmedetomidine in Reducing Shivering After Shivering Cesarean Section Due to Spinal Anesthesia
NCT ID: NCT06711913
Last Updated: 2024-12-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
60 participants
INTERVENTIONAL
2023-12-21
2024-06-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Dexmedetomidine helps to:
1. Reduces shivering and discomfort.
2. Improves patient comfort and satisfaction.
3. Regulates body temperature.
4. Safe and effective.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The exact mechanisms underlying post-spinal shivering are not fully understood, but several factors contribute to its development:
1. \*Hypothermia\*: Spinal anesthesia can cause a decrease in core body temperature, leading to shivering.
2. \*Sympathetic blockade\*: Spinal anesthesia blocks sympathetic nerve fibers, causing vasodilation and decreased blood flow to the extremities.
3. \*Increased oxygen consumption\*: Shivering increases oxygen consumption, which can be detrimental in patients with pre-existing cardiovascular or respiratory disease.
\*Effects of Dexmedetomidine on Post-Spinal Shivering\*
Dexmedetomidine, an alpha-2 adrenergic agonist, has been shown to effectively reduce post-spinal shivering. Its effects include:
1. \*Decreased shivering intensity\*: Dexmedetomidine reduces the severity of shivering, making patients more comfortable.
2. \*Increased core body temperature\*: Dexmedetomidine helps to maintain core body temperature, reducing the likelihood of hypothermia-induced shivering.
3. \*Reduced oxygen consumption\*: By decreasing shivering, dexmedetomidine reduces oxygen consumption, which is beneficial for patients with cardiovascular or respiratory disease.
4. \*Improved patient comfort\*: Dexmedetomidine's sedative and anxiolytic effects contribute to improved patient comfort and satisfaction.
5. \*Reduced need for other anti-shivering interventions\*: Dexmedetomidine's effectiveness in reducing post-spinal shivering may reduce the need for other interventions, such as meperidine, clonidine, or forced-air warming.
Dexmedetomidine's anti-shivering effects are thought to be mediated by its actions on the following mechanisms:
1. \*Alpha-2 adrenergic receptors\*: Dexmedetomidine activates alpha-2 adrenergic receptors, which decreases sympathetic outflow and reduces shivering.
2. \*Hypothalamic thermoregulation\*: Dexmedetomidine may affect the hypothalamus, the body's thermoregulatory center, to reduce shivering and maintain core body temperature.
3. \*Spinal cord mechanisms\*: Dexmedetomidine may also act on the spinal cord to reduce shivering, possibly by inhibiting the release of excitatory neurotransmitters.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention group
Received intravenous dexmedetomidine
Dexmedetomidine
intravenous dexmedetomidine given in form of 100ml infusion over 10 minutes
Control group
control group receive normal saline
Normal Saline (Placebo)
control group receive normal saline as placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dexmedetomidine
intravenous dexmedetomidine given in form of 100ml infusion over 10 minutes
Normal Saline (Placebo)
control group receive normal saline as placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age limit 18 to 35 years
* ASA II
Exclusion Criteria
* hypersensitive to dexmedetomidine
* Pateint with hear, renal, or hepatic diseases requiring follow up
* Pre-eclemptic pateint
* Patient with GA
* Combined spinal epidural anesthesia
18 Years
35 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Liaquat National Hospital & Medical College
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ghulam Fatima
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ghulam Fatima kharl
Role: PRINCIPAL_INVESTIGATOR
Liaquat national hospital and medical college
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Liaquat National Hospital and Medical College
Karachi, Sindh, Pakistan
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Kumar S, Choudhury B, Varikasuvu SR, Singh H, Kumar S, Lahon J, et al. A Systematic Review and Meta-analysis of Efficacy and Safety of Dexmedetomidine Combined With Intrathecal Bupivacaine Compared to Placebo. Cureus. 2022;14(12):e32425.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Dr ghulam fatima
Identifier Type: OTHER
Identifier Source: secondary_id
Liaquat National Hospital 1234
Identifier Type: -
Identifier Source: org_study_id